Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort.

• Tác giả: Federica Alessi, Luigi Battistini, Ginevra Bugani, Sara Caruso, Marta D'Amico, Gabriella d'Ettorre, Mario Falciano, Caterina Fimiani, Alessandro Lazzaro, Maria Gemma Leone, Luca Maddaloni, Claudio Maria Mastroianni, Ivano Mezzaroma, Julieta Morcos, Gregorio Egidio Recchia, Francesco Romano, Letizia Santinelli, Germana Sfara, Ombretta Turriziani
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Antimicrobial agents and chemotherapy , 2025
• Bộ sưu tập: NCBI
• ID: 186725

Tóm tắt

 Doravirine (DOR) is a novel antiretroviral agent with a favorable resistance profile and high tolerability. However, evidence is limited on DOR among elderly people living with HIV (PLWH) and whether it might modulate chronic inflammation. We aimed to investigate the efficacy, safety, and tolerability of DOR as a switching strategy among elderly PLWH and its impact on chronic inflammation in a real-life setting. We recruited a cohort of ART-experienced PLWH undergoing a therapeutic switch to a DOR-based regimen under virologic control (defined as HIV-RNA <
 200 copies/mL), regardless of the previous ART regimen. The primary objective was the evaluation of the rate of virologic control at 48 weeks post-switch. Secondary objectives included analyzing immune and metabolic outcomes. Plasmatic hs-CRP, IL-6, and D-dimer levels were measured as chronic inflammation markers. Overall, 150 PLWH were screened, and 147 were enrolled into the study. A total of 134 PLWH completed the follow-up. The rate of virological control was 96.1% (122/134